Vascular Web Logo

SVS  SVS Foundation

 RR13. Statin Therapy After Infrainguinal Bypass Surgery for Critical Limb Ischemia is Associated with Improved Five-year Survival

​Bjoern D. Suckow1, Larry W. Kraiss1, Andres Schanzer3, David H. Stone2, Jeffrey Kalish4, Randall R. DeMartino2, Jack L. Cronenwett2, Philip P. Goodney2
1University of Utah School of Medicine, Salt Lake City, UT; 2Dartmouth Medical School, Hanover, NH; 3University of Massachusetts Medical School, Worcester, MA; 4Boston University School of Medicine, Boston, MA.

OBJECTIVES: While statin therapy has been linked to fewer short-term complications after lower extremity bypass (LEB), its effect on long-term survival in such patients is uncertain. Therefore, we examined associations between statin use and long-term mortality after LEB.

METHODS: We used the Vascular Study Group of New England registry to study 2,067 patients (71% male, mean age 67 yrs, 67% with CLI) who underwent infrainguinal bypass from 2003-2011. Of these, 1,537 (74%) were on statins peri-operatively and at 1-yr follow-up, while 530 received no statin. We examined crude, adjusted and propensity-matched 5-yr survival (via Social Security Death Index), and 1-yr amputation and graft occlusion rates.

RESULTS: Patients on statins had more coronary disease (38% vs. 22%, p<0.001), diabetes (51% vs. 36%, p<0.001), hypertension (89% vs. 77%, p<0.001) and prior revascularization procedures (50% vs. 38%, p<0.001). Despite higher comorbidity burdens, long-term survival was better for patients on statins in crude (RR=0.7, p<0.001), adjusted (HR=0.7, p=0.001) and propensity- matched analyses (HR=0.7, p=0.03, Figure). In subgroup analysis, a survival advantage was evident in patients with CLI, but not claudication. Statin therapy did not affect 1-yr rates of major amputation (12% vs. 11%, p=0.84) or graft occlusion (20% vs. 18%, p=0.58) in CLI patients.

CONCLUSIONS: While statin therapy confers a five-year survival benefit following LEB, one-year limb-related outcomes are not influenced by statin use.

AUTHOR DISCLOSURES: J. L. Cronenwett, Nothing to disclose; R. R. DeMartino, Nothing to disclose; P. P. Goodney, Nothing to disclose; J. Kalish, Nothing to disclose; L. W. Kraiss, Nothing to disclose; A. Schanzer, Nothing to disclose; D. H. Stone, Nothing to disclose; B. D. Suckow, Nothing to disclose.

RR13.jpg Isolated effect of statin on survival based on the propensity-matched cohort.


Posted April 2012

Contact Us

Society for Vascular Surgery
633 North Saint Clair Street, 22nd Floor | Chicago, IL 60611
Phone: 312-334-2300 | 800-258-7188
Fax: 312-334-2320

Follow Us


VascularWeb® is the prime source for all vascular health and disease information, and is presented by the Society for Vascular Surgery®. Its members are vascular surgeons, specialists, and vascular health professionals who are specialty-trained in all treatments for vascular disease including medical management, non-invasive procedures, and surgery.